Hong Kong Med J 2023 Feb;29(1):79-81 | Epub 27 Jan 2023
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
COMMENTARY
Fighting the Omicron variant: experience in
Shenzhen
B Zhu, PhD; X Han, PhD; J Huang, PhD; D Gu, PhD
School of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, China
Corresponding author: Dr B Zhu (zhub6@sustech.edu.cn)
Almost 5 months after its novel detection in South
Africa, Omicron (B.1.1.529), a SARS-CoV-2 (severe
acute respiratory syndrome coronavirus 2) variant
of concern, spreads prodigiously and globally.1 2 On
27 November 2021, Hong Kong registered its first
confirmed case and shortly thereafter the variant
was detected in Mainland China (9 December
2021). Since then, China has experienced a series
of outbreaks driven by the Omicron variant.
Shenzhen, one of the biggest cities in China, is
geographically adjacent and closely connected to
Hong Kong where cases spiked to tens of thousands,
thus presenting an unprecedented crisis.3 The first
case of Omicron in Shenzhen was registered on 15
January 2022 and triggered an outbreak alarm. The
index case was a worker engaged in collection and
delivery of refrigerated reagents abroad. She was
in close contact with couriers from North America
and wore no personal protection. More Omicron
cases were reported from 12 February onwards.
With the increase in the number of infected cases,
the Shenzhen government implemented a series
of public health measures, such as closing colleges
and suggesting people work from home. Buses
and subways were suspended from 14 to 20 March
to help control the spread of infections (online
supplementary Fig).
The epidemic was mainly triggered by cross-border
movement of individuals between Hong
Kong and Shenzhen. Historically, authorities have
been able to curb the spread of infection at source
and prevent persistent community infection but this
has become extremely difficult due to the fast spread
and short incubation time of Omicron BA.2.4 It has
been almost impossible to track and contain all close
contacts of new cases. As Hong Kong relaxes its
strict pandemic policies and faces a consequent rise
in infection rates, the threat to control the outbreak
in Shenzhen and therefore Mainland China has
become challenging. Of the multi-district outbreaks
in Shenzhen, the largest growth of cases occurred in
Futian district, just across a river from Mai Po and
Yuen Long in Hong Kong. Meanwhile, other districts
such as Baoan, Nanshan, Yantian, and Longgang
have also registered a substantial number of cases.
Based on the ‘dynamic zero–coronavirus disease’ strategy,5 Shenzhen established a leading
group for novel coronavirus prevention and control
planning, incorporating government divisions
and researchers and launched restrictions in
response to these outbreaks. With the increase in
the number of infected cases, Shenzhen decided
to ‘slow down’ from 14 to 20 March 2022. During
this time, Shenzhen launched three rounds of
citywide nucleic acid testing. Employees were
requested to work from home unless considered as
essential workers, including those working in the
water, gas and electricity industry. Businesses were
closed except those selling daily essentials such as
groceries, medicines, and takeout food. All public
transportation was suspended except that between
Shenzhen and Hong Kong. All passengers on flights
or high-speed trains leaving Shenzhen were required
to provide proof of a negative polymerase chain
reaction test result in the 24 hours prior to boarding.
All trucks between Shenzhen and Hong Kong were
asked to change drivers at the border from 14 March
2022. Under strict restrictions, the city resumed
normal work and production from 21 March 2022.
Since then, Shenzhen has managed to control the
number of Omicron cases to a low level, indicating
that Shenzhen’s existing prevention and control
measures are effective against the Omicron variant.
Lessons from the methods adopted in
Shenzhen to contain infection with the Omicron
variant can be summarised as follows. First, early
detection of coronavirus disease 2019 (COVID-19)
cases supported by strong nucleic acid testing
capacity and an effective testing strategy is essential.
Shenzhen set up nucleic acid test sites in a manner
that enabled all residents to reach one within a 15-minute walk from their home or office with waiting
time of less than 30 minutes for a test. Further,
different nucleic acid testing strategies can be applied
to different populations at risk (Table). For example,
travellers arriving at Shenzhen from high-risk
COVID-19 areas must undergo a 7-day centralised
quarantine, inbound arrivals are subject to a 7-day
centralised quarantine as well as 3-day home health
monitoring. Second, response to newly infected
COVID-19 cases (the ‘1-4-6-24 principle’) should be
rapid. After reporting of primary screening positive cases, the epidemiological investigation team arrived
at the location of the confirmed case within 1 hour,
then completed the preliminary epidemiological
investigation and identified relevant individuals
(eg, close contacts and secondary contacts) within
4 hours, followed by transportation of these
individuals to quarantine hotels and implementation
of control measures in key regions within 6 hours, and
finally with nucleic acid testing and epidemiological
investigation of relevant individuals implemented
within 24 hours. This could not have been achieved
without the growing epidemiological investigation
team composed of different government sectors (the
Chinese Center for Disease Control and Prevention,
the Police, the Ministry of Industry and Information
Technology, etc) in Shenzhen. Third, quarantine and
hospital bed spaces should be increased. Shenzhen
tried to improve the supply of quarantine rooms
by using hotels, commercial properties and school
dormitories, with capacity of quarantine spaces
reaching 100 000. From 28 January 2020, it took
only 20 days to build an emergency isolation area
(separated from the hospital headquarters by
hills) at The Third People’s Hospital of Shenzhen,
with 800 negative pressure beds out of a total
of 1600. It is the city’s designated COVID-19
treatment facility and comprises an emergency
ward, living and logistics areas and an independent
medical and nursing team. Fourth, with non-stop
emergency patient transport and a ‘white list’ of daily
essentials to supply personnel when strict public
health measures in place, communities could collect
information about emergency patients (dialysis
patients, patients with mental disorders, pregnant
women, and the elderly people) and send patients to
designated hospitals without delay. The government released the ‘white list’ of 674 daily necessity supply
enterprises in Shenzhen, covering suppliers of daily
basic goods such as food production companies,
large chain supermarkets and e-commerce entities.
They also established a ‘white list’ for take-away
catering and daily-necessity delivery personnel,
covering 14 000 online stores and 47 000 delivery
employees in key supply enterprises.
Table. Shenzhen’s nucleic acid testing and quarantine strategy for populations at risk (August 2022)
At the time of writing this article, Shenzhen
continued to apply its ‘dynamic zero–coronavirus
disease’ policy to bring COVID-19 under control
with minimum social cost in the shortest time
possible to effectively protect the health of the local
population. Although the Omicron variant is more
transmissible than its predecessor and is now the
dominant variant, Shenzhen’s experience shows that
strong public health measures remain effective.
Author contributions
Concept or design: B Zhu.
Acquisition of data: D Gu.
Analysis or interpretation of data: B Zhu.
Drafting of the manuscript: B Zhu.
Critical revision of the manuscript for important intellectual content: X Han, J Huang, D Gu.
Acquisition of data: D Gu.
Analysis or interpretation of data: B Zhu.
Drafting of the manuscript: B Zhu.
Critical revision of the manuscript for important intellectual content: X Han, J Huang, D Gu.
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
Conflicts of interest
All authors have disclosed no conflicts of interest.
Funding/support
This study was funded by the Shenzhen Science and Technology Innovation Commission, China (Grant Nos.: JSGG20220301090202005 and JCYJ20220530113208019).
The funder had no role in study design, data collection/analysis/interpretation or manuscript preparation.
References
1. Karim SS, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 2021;398:2126-8. Crossref
2. Ma K, Chen J. Omicron XE emerges as SARS-CoV-2 keeps evolving. Innovation (Camb) 2022;3:100248. Crossref
3. Lewis D. Will Omicron finally overpower China’s COVID defences? Nature 2022;604:17-8. Crossref
4. Yuan W, Hou Y, Lin Q, Chen L, Ren T. How China responds to Omicron. J Infect 2022;85:90-122. Crossref
5. Liu J, Liu M, Liang W. The dynamic COVID-zero strategy in China. China CDC Wkly 2022;4:74-5. Crossref